Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.

about

Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.

Item

http://www.wikidata.org/entity/Q53841619

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Alpha-1 antitrypsin treatment ...... s safety and pharmacokinetics.

@en

Alpha-1 antitrypsin treatment ...... s safety and pharmacokinetics.

@nl

type

Item

label

Alpha-1 antitrypsin treatment ...... s safety and pharmacokinetics.

@en

Alpha-1 antitrypsin treatment ...... s safety and pharmacokinetics.

@nl

prefLabel

Alpha-1 antitrypsin treatment ...... s safety and pharmacokinetics.

@en

Alpha-1 antitrypsin treatment ...... s safety and pharmacokinetics.

@nl

P1476

Alpha-1 antitrypsin treatment ...... ss safety and pharmacokinetics

@en

P2093

Alice Long

http://www.w3.org/2001/XMLSchema#string

Brett Jepson

http://www.w3.org/2001/XMLSchema#string

Deborah Phippard

http://www.w3.org/2001/XMLSchema#string

ITN RETAIN Study Team

http://www.w3.org/2001/XMLSchema#string

James G McNamara

http://www.w3.org/2001/XMLSchema#string

Kristina M Harris

http://www.w3.org/2001/XMLSchema#string

Lia J Weiner

http://www.w3.org/2001/XMLSchema#string

Maria Koulmanda

http://www.w3.org/2001/XMLSchema#string

Mario R Ehlers

http://www.w3.org/2001/XMLSchema#string

Sai Kanaparthi

http://www.w3.org/2001/XMLSchema#string

P2860

The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Serpin structure, mechanism, and function

Therapeutic targeting of NOD1 receptors

The role of TNF-α in mice with type 1- and 2- diabetes

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

P304

945-954

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PEDI.12660

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gordon C Weir

P577

2018-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29473705

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

phase I clinical trial

P932

6030471

http://www.w3.org/2001/XMLSchema#string